| Compound | Pinealon |
|---|---|
| Category | Khavinson brain bioregulator |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers Pinealon, a khavinson brain bioregulator, graded "Minimal evidence" in this catalog's evidence system. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A short glutamate-aspartate-containing tripeptide from the Khavinson bioregulator family, claimed to be brain-tissue specific.
Mechanism of Action
Proposed effects involve regulation of gene expression in neuronal tissue, based on the bioregulation theory of short peptides.
Research and Evidence
Russian-language preclinical and small clinical literature only; no international trials.
Safety and Side Effects
Sparse safety data; research-grade sourcing caveat.
Frequently Asked Questions
What is the evidence tier of Pinealon?
Pinealon is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Pinealon an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Pinealon?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Pinealon studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.